1rh2 › Citations

Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography.

Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR
Structure 4 1453-63 (1996)
Cited: 131 times
EuropePMC logo PMID: 8994971

Abstract

Background

The human alpha-interferon (huIFN-alpha) family displays broad spectrum antiviral, antiproliferative and immunomodulatory activities on a variety of cell types. The diverse biological activities of the IFN-alpha's are conveyed to cells through specific interactions with cell-surface receptors. Despite considerable effort, no crystal structure of a member of this family has yet been reported, because the quality of the protein crystals have been unsuitable for crystallographic studies. Until now, structural models of the IFN-alpha's have been based on the structure of murine IFN-beta (muIFN-beta). These models are likely to be inaccurate, as the amino acid sequence of muIFN-beta differs significantly from the IFN-alpha's at proposed receptor-binding sites. Structural information on a huIFN-alpha subtype would provide an improved basis for modeling the structures of the entire IFN-alpha family.

Results

The crystal structure of recombinant human interferon-alpha 2b (huIFN-alpha 2b) has been determined at 2.9 A resolution. HuIFN-alpha 2b exists in the crystal as a noncovalent dimer, which associates in a novel manner. Unlike other structurally characterized cytokines, extensive interactions in the dimer interface are mediated by a zinc ion (Zn2+). The overall fold of huIFN-alpha 2b is most similar to the structure of muIFN-beta. Unique to huIFN-alpha 2b is a 3(10) helix in the AB loop which is held to the core of the molecule by a disulfide bond.

Conclusion

The structure of huIFN-alpha 2b provides an accurate model for analysis of the > 15 related type 1 interferon molecules. HuIFN-alpha 2b displays considerable structural similarity with muIFN-beta, interleukin-10 and interferon-gamma, which also bind related class 2 cytokine receptors. From these structural comparisons and numerous studies on the effects of mutations on biological activity, we have identified protein surfaces that appear to be important in receptor activation. This study also reveals the potential biological importance of the huIFN-alpha 2b dimer.

Reviews - 1rh2 mentioned but not cited (3)

  1. Approved Antiviral Drugs over the Past 50 Years. De Clercq E, Li G. Clin Microbiol Rev 29 695-747 (2016)
  2. Lambda Interferons: New Cytokines with Old Functions. Hamming OJ, Gad HH, Paludan S, Hartmann R. Pharmaceuticals (Basel) 3 795-809 (2010)
  3. Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target. Olenginski LT, Attionu SK, Henninger EN, LeBlanc RM, Longhini AP, Dayie TK. Viruses 15 1913 (2023)

Articles - 1rh2 mentioned but not cited (5)

  1. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. J Biol Chem 284 20869-20875 (2009)
  2. Crystal structure of Zebrafish interferons I and II reveals conservation of type I interferon structure in vertebrates. Hamming OJ, Lutfalla G, Levraud JP, Hartmann R. J Virol 85 8181-8187 (2011)
  3. Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab. Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF. J Biol Chem 290 14979-14985 (2015)
  4. Two different unique cardiac isoforms of protein 4.1R in zebrafish, Danio rerio, and insights into their cardiac functions as related to their unique structures. Murata K, Nunomura W, Takakuwa Y, Cherr GN. Dev Growth Differ 52 591-602 (2010)
  5. Production of bioactive liver-targeting interferon Mu-IFN-CSP by soluble prokaryotic expression. Liu A, Gui S, Zhang L, Chen Z, Tang Y, Xiao M, Wang J, Liu W, Jin X, Zhu J, Lu X. AMB Express 7 192 (2017)


Reviews citing this publication (28)

  1. Interferons, interferon-like cytokines, and their receptors. Pestka S, Krause CD, Walter MR. Immunol Rev 202 8-32 (2004)
  2. Interleukin-10 and related cytokines and receptors. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Annu Rev Immunol 22 929-979 (2004)
  3. The Role of Zinc in Antiviral Immunity. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. Adv Nutr 10 696-710 (2019)
  4. The interferon system of teleost fish. Robertsen B. Fish Shellfish Immunol 20 172-191 (2006)
  5. The interferons: 50 years after their discovery, there is much more to learn. Pestka S. J Biol Chem 282 20047-20051 (2007)
  6. Interleukin-6: structure-function relationships. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Protein Sci 6 929-955 (1997)
  7. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Adv Drug Deliv Rev 54 547-570 (2002)
  8. The type I interferon receptor: structure, function, and evolution of a family business. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G. J Interferon Cytokine Res 19 1069-1098 (1999)
  9. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Piehler J, Thomas C, Garcia KC, Schreiber G. Immunol Rev 250 317-334 (2012)
  10. Roles of Zinc Signaling in the Immune System. Hojyo S, Fukada T. J Immunol Res 2016 6762343 (2016)
  11. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Krause CD, Pestka S. Pharmacol Ther 106 299-346 (2005)
  12. The human interferon alpha species and receptors. Pestka S. Biopolymers 55 254-287 (2000)
  13. Pegylated interferons for the treatment of chronic hepatitis C infection. Luxon BA, Grace M, Brassard D, Bordens R. Clin Ther 24 1363-1383 (2002)
  14. Biological assays for interferons. Meager A. J Immunol Methods 261 21-36 (2002)
  15. Interferon-delta: the first member of a novel type I interferon family. Lefèvre F, Guillomot M, D'Andréa S, Battegay S, La Bonnardière C. Biochimie 80 779-788 (1998)
  16. Type I interferons and limitin: a comparison of structures, receptors, and functions. Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y. Cytokine Growth Factor Rev 12 337-348 (2001)
  17. The Role of Structure in the Biology of Interferon Signaling. Walter MR. Front Immunol 11 606489 (2020)
  18. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Asmana Ningrum R. Scientifica (Cairo) 2014 970315 (2014)
  19. IFNA2: The prototypic human alpha interferon. Paul F, Pellegrini S, Uzé G. Gene 567 132-137 (2015)
  20. Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes. Wittling MC, Cahalan SR, Levenson EA, Rabin RL. Front Immunol 11 605673 (2020)
  21. Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Walter MR, Bordens R, Nagabhushan TL, Williams BR, Herberman RB, Dinarello CA, Borden EC, Trotta PP, Pestka S, Pfeffer LM. Cancer Biother Radiopharm 13 143-154 (1998)
  22. Interferon-Inducible Myxovirus Resistance Proteins: Potential Biomarkers for Differentiating Viral from Bacterial Infections. Zav'yalov VP, Hämäläinen-Laanaya H, Korpela TK, Wahlroos T. Clin Chem 65 739-750 (2019)
  23. The structure of human interferon lambda and what it has taught us. Gad HH, Hamming OJ, Hartmann R. J Interferon Cytokine Res 30 565-571 (2010)
  24. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Grace MJ, Cutler D. Antivir Chem Chemother 15 287-297 (2004)
  25. Therapeutic alpha-interferons protein: structure, production, and biosimilar. El-Baky NA, Redwan EM, Redwan EM. Prep Biochem Biotechnol 45 109-127 (2015)
  26. A new decoration for nitric oxide synthase - a Zn(Cys)4 site. Ludwig ML, Marletta MA. Structure 7 R73-9 (1999)
  27. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation. Castro LS, Lobo GS, Pereira P, Freire MG, Neves MC, Pedro AQ. Vaccines (Basel) 9 328 (2021)
  28. Recombinant interferon-beta therapy and neuromuscular disorders. Stübgen JP. J Neuroimmunol 212 132-141 (2009)

Articles citing this publication (95)

  1. IL-28, IL-29 and their class II cytokine receptor IL-28R. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. Nat Immunol 4 63-68 (2003)
  2. Structural linkage between ligand discrimination and receptor activation by type I interferons. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC. Cell 146 621-632 (2011)
  3. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. Pharm Res 15 641-649 (1998)
  4. The crystal structure of human interferon beta at 2.2-A resolution. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. Proc Natl Acad Sci U S A 94 11813-11818 (1997)
  5. Atlantic salmon interferon genes: cloning, sequence analysis, expression, and biological activity. Robertsen B, Bergan V, Røkenes T, Larsen R, Albuquerque A. J Interferon Cytokine Res 23 601-612 (2003)
  6. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. J Mol Biol 274 661-675 (1997)
  7. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R. J Interferon Cytokine Res 21 1103-1115 (2001)
  8. Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2. Piehler J, Schreiber G. J Mol Biol 289 57-67 (1999)
  9. Identification of an Atlantic salmon IFN multigene cluster encoding three IFN subtypes with very different expression properties. Sun B, Robertsen B, Wang Z, Liu B. Dev Comp Immunol 33 547-558 (2009)
  10. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van der Linden EC, Bayer RJ, Tarp MA, Clausen H. Glycobiology 16 833-843 (2006)
  11. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, Zhao Z, Navarro MB, Kirschman KD, Bykadi S, Jubin RG, Rabin RL. Immunol Cell Biol 90 774-783 (2012)
  12. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. Piehler J, Schreiber G. J Mol Biol 294 223-237 (1999)
  13. Shared receptor components but distinct complexes for alpha and beta interferons. Lewerenz M, Mogensen KE, Uzé G. J Mol Biol 282 585-599 (1998)
  14. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. Takagi H, Nagamine T, Abe T, Takayama H, Sato K, Otsuka T, Kakizaki S, Hashimoto Y, Matsumoto T, Kojima A, Takezawa J, Suzuki K, Sato S, Mori M. J Viral Hepat 8 367-371 (2001)
  15. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. Ko WS, Guo CH, Yeh MS, Lin LY, Hsu GS, Chen PC, Luo MC, Lin CY. World J Gastroenterol 11 4697-4702 (2005)
  16. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. Roisman LC, Jaitin DA, Baker DP, Schreiber G. J Mol Biol 353 271-281 (2005)
  17. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, Afkhamizarreh F, Durocher Y. BMC Biotechnol 8 65 (2008)
  18. The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Chill JH, Quadt SR, Levy R, Schreiber G, Anglister J. Structure 11 791-802 (2003)
  19. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity. Slutzki M, Jaitin DA, Yehezkel TB, Schreiber G. J Mol Biol 360 1019-1030 (2006)
  20. Characterization of the porcine alpha interferon multigene family. Cheng G, Chen W, Li Z, Yan W, Zhao X, Xie J, Liu M, Zhang H, Zhong Y, Zheng Z. Gene 382 28-38 (2006)
  21. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M. Biochimie 90 437-449 (2008)
  22. Salmonids have an extraordinary complex type I IFN system: characterization of the IFN locus in rainbow trout oncorhynchus mykiss reveals two novel IFN subgroups. Zou J, Gorgoglione B, Taylor NG, Summathed T, Lee PT, Panigrahi A, Genet C, Chen YM, Chen TY, Ul Hassan M, Mughal SM, Boudinot P, Secombes CJ. J Immunol 193 2273-2286 (2014)
  23. Zinc is a potent and specific inhibitor of IFN-λ3 signalling. Read SA, O'Connor KS, Suppiah V, Ahlenstiel CLE, Obeid S, Cook KM, Cunningham A, Douglas MW, Hogg PJ, Booth D, George J, Ahlenstiel G. Nat Commun 8 15245 (2017)
  24. Crystal structure of ovine interferon-tau at 2.1 A resolution. Radhakrishnan R, Walter LJ, Subramaniam PS, Johnson HM, Walter MR. J Mol Biol 286 151-162 (1999)
  25. Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-based model of the complex. Quadt-Akabayov SR, Chill JH, Levy R, Kessler N, Anglister J. Protein Sci 15 2656-2668 (2006)
  26. Molecular characterisation and structural analysis of an interferon homologue in sea bass (Dicentrarchus labrax L.). Casani D, Randelli E, Costantini S, Facchiano AM, Zou J, Martin S, Secombes CJ, Scapigliati G, Buonocore F. Mol Immunol 46 943-952 (2009)
  27. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions. Gilbert HE, Asokan R, Holers VM, Perkins SJ. J Mol Biol 362 1132-1147 (2006)
  28. A structural basis for interferon-alpha-receptor interactions. Kumaran J, Wei L, Kotra LP, Fish EN. FASEB J 21 3288-3296 (2007)
  29. Crystal structure of the oxidised and reduced acidic cytochrome c3from Desulfovibrio africanus. Nørager S, Legrand P, Pieulle L, Hatchikian C, Roth M. J Mol Biol 290 881-902 (1999)
  30. Expression of a novel murine type I IFN in the pancreatic islets induces diabetes in mice. Vassileva G, Chen SC, Zeng M, Abbondanzo S, Jensen K, Gorman D, Baroudy BM, Jiang Y, Murgolo N, Lira SA. J Immunol 170 5748-5755 (2003)
  31. The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling. Li Z, Strunk JJ, Lamken P, Piehler J, Walz T. J Mol Biol 377 715-724 (2008)
  32. The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Ko WS, Guo CH, Hsu GS, Chiou YL, Yeh MS, Yaun SR. Clin Biochem 38 614-620 (2005)
  33. Development of a cultivation process for the enhancement of human interferon alpha 2b production in the oleaginous yeast, Yarrowia lipolytica. Gasmi N, Ayed A, Ammar BB, Zrigui R, Nicaud JM, Kallel H. Microb Cell Fact 10 90 (2011)
  34. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains. Arduini RM, Strauch KL, Runkel LA, Carlson MM, Hronowski X, Foley SF, Young CN, Cheng W, Hochman PS, Baker DP. Protein Sci 8 1867-1877 (1999)
  35. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. Jones TD, Hanlon M, Smith BJ, Heise CT, Nayee PD, Sanders DA, Hamilton A, Sweet C, Unitt E, Alexander G, Lo KM, Gillies SD, Carr FJ, Baker MP. J Interferon Cytokine Res 24 560-572 (2004)
  36. The function of the human interferon-beta 1a glycan determined in vivo. Dissing-Olesen L, Thaysen-Andersen M, Meldgaard M, Højrup P, Finsen B. J Pharmacol Exp Ther 326 338-347 (2008)
  37. Intronless and intron-containing type I IFN genes coexist in amphibian Xenopus tropicalis: Insights into the origin and evolution of type I IFNs in vertebrates. Gan Z, Chen SN, Huang B, Hou J, Nie P. Dev Comp Immunol 67 166-176 (2017)
  38. Physicochemical and biological assays for quality control of biopharmaceuticals: interferon alpha-2 case study. Silva MM, Lamarre B, Cerasoli E, Rakowska P, Hills A, Bailey MJ, Wheeler JX, Burns CJ, Gaines-Das RE, Jones C, Robinson CJ. Biologicals 36 383-392 (2008)
  39. Intermolecular interactions in a 44 kDa interferon-receptor complex detected by asymmetric reverse-protonation and two-dimensional NOESY. Nudelman I, Akabayov SR, Schnur E, Biron Z, Levy R, Xu Y, Yang D, Anglister J. Biochemistry 49 5117-5133 (2010)
  40. Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R. Harris BD, Schreiter J, Chevrier M, Jordan JL, Walter MR. J Biol Chem 293 16057-16068 (2018)
  41. NMR mapping of the IFNAR1-EC binding site on IFNalpha2 reveals allosteric changes in the IFNAR2-EC binding site. Akabayov SR, Biron Z, Lamken P, Piehler J, Anglister J. Biochemistry 49 687-695 (2010)
  42. Characterization and virus-induced expression profiles of the porcine interferon-omega multigene family. Zhao X, Cheng G, Yan W, Liu M, He Y, Zheng Z. J Interferon Cytokine Res 29 687-693 (2009)
  43. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping. Bello-Rivero I, Cervantes M, Torres Y, Ferrero J, Rodríguez E, Pérez J, García I, Díaz G, López-Saura P. J Autoimmun 23 63-73 (2004)
  44. Human IFN-alpha protein engineering: the amino acid residues at positions 86 and 90 are important for antiproliferative activity. Hu R, Bekisz J, Schmeisser H, McPhie P, Zoon K. J Immunol 167 1482-1489 (2001)
  45. Anti-viral effects of interferon administration on sevenband grouper, Epinephelus septemfasciatus. Ohta T, Ueda Y, Ito K, Miura C, Yamashita H, Miura T, Tozawa Y. Fish Shellfish Immunol 30 1064-1071 (2011)
  46. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY. Clin Cancer Res 23 2038-2049 (2017)
  47. A new IFN-like cytokine, limitin, modulates the immune response without influencing thymocyte development. Takahashi I, Kosaka H, Oritani K, Heath WR, Ishikawa J, Okajima Y, Ogawa M, Kawamoto S, Yamada M, Azukizawa H, Itami S, Yoshikawa K, Tomiyama Y, Matsuzawa Y. J Immunol 167 3156-3163 (2001)
  48. Demonstrating the stability of albinterferon alfa-2b in the presence of silicone oil. Auge KB, Blake-Haskins AW, Devine S, Rizvi S, Li YM, Hesselberg M, Orvisky E, Affleck RP, Spitznagel TM, Perkins MD. J Pharm Sci 100 5100-5114 (2011)
  49. Development of next generation of therapeutic IFN-α2b via genetic code expansion. Zhang B, Xu H, Chen J, Zheng Y, Wu Y, Si L, Wu L, Zhang C, Xia G, Zhang L, Zhou D. Acta Biomater 19 100-111 (2015)
  50. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta. Platis D, Foster GR. J Interferon Cytokine Res 23 655-666 (2003)
  51. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Wylie DC, Voloch M, Lee S, Liu YH, Cannon-Carlson S, Cutler C, Pramanik B. Pharm Res 18 1354-1360 (2001)
  52. Characterization and antivirus activities of a novel bovine IFN-omega24. Luo X, Guo Y, Bao J, Liu Y, An D, Ma B, Gao M, Wang J. Mol Immunol 66 357-363 (2015)
  53. Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine. Harris BD, Kuruganti S, Deshpande A, Goepfert PA, Chatham WW, Walter MR. Lupus 29 1095-1105 (2020)
  54. High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli. Platis D, Foster GR. Protein Expr Purif 31 222-230 (2003)
  55. Unique Composition of Intronless and Intron-Containing Type I IFNs in the Tibetan Frog Nanorana parkeri Provides New Evidence To Support Independent Retroposition Hypothesis for Type I IFN Genes in Amphibians. Gan Z, Yang YC, Chen SN, Hou J, Laghari ZA, Huang B, Li N, Nie P. J Immunol 201 3329-3342 (2018)
  56. Construction, expression and characterization of human interferon alpha2b-(G4S)n-thymosin alpha1 fusion proteins in Pichia pastoris. Yang YF, Yuan HY, Liu NS, Chen XL, Gao BY, Lu H, Li YY. World J Gastroenterol 11 2597-2602 (2005)
  57. Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b. Gull I, Samra ZQ, Aslam MS, Athar MA. Springerplus 2 264 (2013)
  58. Identification of a linear epitope of interferon-alpha2b recognized by neutralizing monoclonal antibodies. Blank VC, Sterin-Prync A, Retegui L, Vidal A, Criscuolo M, Roguin LP. Eur J Biochem 265 11-19 (1999)
  59. N-glycosylation of murine IFN-beta in a putative receptor-binding region. Sommereyns C, Michiels T. J Interferon Cytokine Res 26 406-413 (2006)
  60. Protein quaternary structures in solution are a mixture of multiple forms. Marciano S, Dey D, Listov D, Fleishman SJ, Sonn-Segev A, Mertens H, Busch F, Kim Y, Harvey SR, Wysocki VH, Schreiber G. Chem Sci 13 11680-11695 (2022)
  61. Altering the central carbon metabolism of HEK293 cells: Impact on recombinant glycoprotein quality. Karengera E, Robotham A, Kelly J, Durocher Y, De Crescenzo G, Henry O. J Biotechnol 242 73-82 (2017)
  62. Characterization of N-terminal interferon tau mutants: P26L affords enhanced activity and lack of toxicity. Shorts LH, Dancz CE, Shupp JW, Pontzer CH. Exp Biol Med (Maywood) 229 194-202 (2004)
  63. Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes. Kuruganti S, Miersch S, Deshpande A, Speir JA, Harris BD, Schriewer JM, Buller RM, Sidhu SS, Walter MR. J Biol Chem 291 447-461 (2016)
  64. Protein spherulites for sustained release of interferon: preparation, characterization and in vivo evaluation. Jiang Y, Shi K, Xia D, Wang S, Song T, Cui F. J Pharm Sci 100 1913-1922 (2011)
  65. Structural and functional heterogeneity of the amino-terminal receptor-binding domain of human interferon-alpha 2. Kontseková E, Liptáková H, Mucha V, Kontsek P. Int J Biol Macromol 24 11-14 (1999)
  66. Ectoine and hydroxyectoine inhibit thermal-induced aggregation and increase thermostability of recombinant human interferon Alfa2b. Salmannejad F, Nafissi-Varcheh N. Eur J Pharm Sci 97 200-207 (2017)
  67. Site-specific derivatization of human interferon β-1a at lysine residues using microbial transglutaminase. Spolaore B, Forzato G, Fontana A. Amino Acids 50 923-932 (2018)
  68. Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab. Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. Protein Sci 24 1440-1450 (2015)
  69. Antagonist peptides of human interferon-alpha2b isolated from phage display library inhibit interferon induced antiviral activity. Tian W, Bai G, Li ZH, Yang WB. Acta Pharmacol Sin 27 1044-1050 (2006)
  70. Functional characterization of monoclonal antibodies to interferon-tau. Swann SL, Bazer FW, Villarete LH, Chung A, Pontzer CH. Hybridoma 18 399-405 (1999)
  71. Multiple conformational states of a new hematopoietic cytokine (megakaryocyte growth and development factor): pH- and urea-induced denaturation. Hamburger JB, Chen E, Narhi LO, Wu GM, Brems DN. Proteins 32 495-503 (1998)
  72. A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family. Miersch S, Kuruganti S, Walter MR, Sidhu SS. Protein Eng Des Sel 30 697-704 (2017)
  73. Antibodies against IFN gamma-binding proteins recognize a member of IFN alpha R complex. Bello I, Rodes L, Saura PL. Biochem Biophys Res Commun 280 1197-1202 (2001)
  74. Effects of solution conditions on methionine oxidation in albinterferon alfa-2b and the role of oxidation in its conformation and aggregation. Chou DK, Krishnamurthy R, Manning MC, Randolph TW, Carpenter JF. J Pharm Sci 102 660-673 (2013)
  75. Identification of antiviral mimetic peptides with interferon alpha-2b-like activity from a random peptide library using a novel functional biopanning method. Zhang Q, Bai G, Chen JQ, Tian W, Cao Y, Pan PW, Wang C. Acta Pharmacol Sin 29 634-640 (2008)
  76. Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation. Shi K, Cui F, Bi H, Jiang Y, Shi H, Song T. Pharm Res 30 269-279 (2013)
  77. Amino acid substitutions in loop BC and helix C affect antigenic properties of helix D in hybrid IFN-alpha21a/alpha2c molecules. Schmeisser H, Hu R, Kontsek P, Bekisz J, Zoon K. J Interferon Cytokine Res 22 463-472 (2002)
  78. Comparative Toxicity of Interferon Beta-1a Impurities of Heavy Metal Ions. Berillo D. Medicina (Kaunas) 58 463 (2022)
  79. Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-interferon antibody fragment and human interferon alpha-2A. Oganesyan V, Damschroder MM, Cook KE, Wu H, Dall'Acqua WF. Acta Crystallogr Sect F Struct Biol Cryst Commun 65 14-16 (2009)
  80. Preparation and characterization of latex films photo-immobilized with IFN-α. Wu L, Hu K, Zhang L, Chen W, Chen X, You R, Yin L, Guan YQ. Colloids Surf B Biointerfaces 145 104-113 (2016)
  81. Quantitative evaluation of protein conformation in pharmaceuticals using cross-linking reactions coupled with LC-MS/MS analysis. Yamaguchi H, Hirakura Y, Shirai H, Mimura H, Toyo'oka T. J Pharm Biomed Anal 55 574-582 (2011)
  82. Synthesis and biological properties of chimeric interferon-alpha2b peptides. Peña C, Blank VC, Marino VJ, Roguin LP. Peptides 26 1144-1149 (2005)
  83. The carboxyterminal domains of human IFN-alpha2 and IFN-alpha8 are antigenically homologous. Vancová I, Kontseková E, Mucha V, Kontsek P. J Interferon Cytokine Res 20 455-461 (2000)
  84. A morphological screening of protein crystals for interferon delivery by metal ion-chelate technology. Jiang Y, Shi K, Wang S, Li X, Cui F. Drug Dev Ind Pharm 36 1389-1397 (2010)
  85. Analysis of the Differential Expression and Antiviral Activity of Porcine Interferon-α In Vitro. Fang J, Zhang Q, Xi Y, Lang L, Wang K, Li S. Int J Pept Res Ther 29 42 (2023)
  86. Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin. Hermanrud C, van Capel TMM, Auer M, Karrenbauer V, Deisenhammer F, de Jong EC, Fogdell-Hahn A. J Interferon Cytokine Res 39 302-313 (2019)
  87. Disclosing the Potential of Fluorinated Ionic Liquids as Interferon-Alpha 2b Delivery Systems. Ferreira ML, Vieira NSM, Oliveira ALS, Araújo JMM, Pereiro AB. Nanomaterials (Basel) 12 1851 (2022)
  88. Electrostatics Drive Oligomerization and Aggregation of Human Interferon Alpha-2a. Pohl C, Polimeni M, Indrakumar S, Streicher W, Peters GHJ, Nørgaard A, Lund M, Harris P. J Phys Chem B 125 13657-13669 (2021)
  89. Evaluation of adverse effects of mutein forms of recombinant human interferon alpha-2b in female swiss webster mice. Rachmawati H, Merika A, Ningrum RA, Anggadiredja K, Retnoningrum DS. Biomed Res Int 2013 943687 (2013)
  90. Interferon dimers: IFN-PEG-IFN. Herrington-Symes A, Choi JW, Brocchini S. J Drug Target 25 881-890 (2017)
  91. Interferon-alpha-2a and zinc combination therapy in children with chronic hepatitis B infection. Kuloğlu Z, Kırbaş G, Erden E, Kansu A. Biol Trace Elem Res 143 1302-1309 (2011)
  92. N-terminal amino acids of bovine alpha interferons are relevant for the neutralization of their antiviral activity. Barreto Filho JB, Eiras PR, Golgher RR. Braz J Med Biol Res 34 663-667 (2001)
  93. Retraction notice. Muscle Nerve 55 766 (2017)
  94. Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1B and a poly-ARG interferon beta-1B analogue. Dubey S, Perozzo R, Scapozza L, Kalia YN. Int J Pharm X 2 100051 (2020)
  95. Targeted mutations in IFNα2 improve its antiviral activity against various viruses. Karakoese Z, Le-Trilling V-TK, Schuhenn J, Francois S, Lu M, Liu J, Trilling M, Hoffmann D, Dittmer U, Sutter K. mBio e0235723 (2023)


Quick links